Dossier assessment
Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD1 or PD-L1 inhibitor
- Patients for whom chemotherapy is suitable: hint of minor added benefit
- Patients for whom chemotherapy is unsuitable: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-12-01 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A22-61
- Commission
- Commission awarded on 25.05.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Enfortumab vedotin (urothelial carcinoma) – Addendum to Commission A22-61
Status: Commission completed
-
Addendum
Enfortumab vedotin (urothelial cancer) – 2nd addendum to commission A22-61
Status: Commission completed
-
Dossier assessment
Enfortumab vedotin (urothelial cancer, neoadjuvant + adjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Enfortumab vedotin (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed